Dementia with Lewy bodies. Clinical improvement under treatment with an acetylcholinesterase inhibitor;Demenz mit Lewy-körperchen. Besserung unter therapie mit einem acetylcholinesteraseinhibitor

Nervenarzt

Volumn 78, Issue 9, 2007, Pages 1052-1057

  Omerovic, M ^a   Teipel, S J ^a   Hampel, T ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Alzheimer's dementia; Behavioural symptoms; Cholinergic deficit; Cholinesterase inhibitors; Dementia with Lewy bodies; Neuroleptics; Parkinson dementia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENSERAZIDE; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; LEVODOPA; QUETIAPINE;

AGED; ANAMNESIS; ARTICLE; CASE REPORT; COGNITION; DEMENTIA; HUMAN; LEWY BODY; TREATMENT RESPONSE; VISUAL HALLUCINATION;

AGED; CHOLINESTERASE INHIBITORS; HALLUCINATIONS; HUMANS; INDANS; LEWY BODY DISEASE; MALE; MENTAL DISORDERS; PIPERIDINES; TREATMENT OUTCOME;

EID: 34548577764     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-007-2277-1     Document Type: Article

References (28)

1. Aarsland D, Ballard C, Larsen JP, McKeith I (2001) A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 16: 528-536
2. Baba M, Nakajo S, Tu PH et al. (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152: 879-884
3. Ballard CG, Aarsland D, McKeith IG et al. (2002) Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 59: 1714-1720
4. Ballard C, Piggott M, Johnson M et al. (2000) Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 48: 868-876
5. Cummings JL, Mega M, Gray K et al. (1994) The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44: 2308-2314
6. Folstein MF, Folstein SE, McHugh PR (1975).,Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198
7. Gnanalingham KK, Byrne EJ,Thornton A et al. (1997) Motor and cognitive function in Lewy body dementia: comparison with Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiatry 62: 243-252
8. Heyman A,Fillenbaum GG, Gearing M et al. (1999) Comparison of Lewy body variant of Alzheimer's disease with pure Alzheimer's disease. Neurology 52: 1839-1844
9. Jellinger KA (1999) The frequency of Lewy bodies in a consecutive autopsy series. Clin Neuropathol 18: 214-215
10. Lanctôt KL, Herrmann N (2000) Donepezil for behavioural disorders associated with Lewy bodies: a case series. Int J Geriatr Psychiatry 15: 338-345
11. Langlais PJ, Thal L, Hansen L et al. (1993) Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology 43: 1927-1934
12. Lebert F, Pasquier F, Souliez L et al. (1998) Tacrine efficacy in Lewy body dementia. Int J Geriatr Psychiatry 13: 516-519
13. Lewy FH (1912) Paralysis agitans: I. Pathologische Anatomie. In: Lewandowsky M (Hrsg) Handbuch der Neurologie. Vol 3. Springer, Berlin, S 920-933
14. McKeith et al. (2005) Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium Neurology 65: 1863
15. McKeith IG, Del Ser T, Spano PF et al. (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356: 2031-2036
16. McKeith IG, Galasko D, Kosaka K et al. (1996) Consensus guidlines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB). Neurology 47: 1113-1124
17. McKeith IG, Perry RH, Fairbairn AF et al. (1992) Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 22: 911-922
18. Perry EK, Marshall E, Perry RH et al. (1990) Cholinergic and dopaminergic activities in senile dementia of Lewy body type. Alzheimer Dis Assoc Disord 4: 87-96
19. Perry EK et al. (1991) Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease. Ann N Y Acad Sci 640: 197-202
20. Perry RH, McKeith IG, Perry EK (1996) Introduction. In: Perry R, McKeith I, Perry E (eds) Dementia with Lewy bodies. Cambridge Univ Press, Cambridge, pp 1-5
21. Querfurth HW, Allam GJ, Geffroy MA et al. (2000) Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial. Dement Geriatr Cogn Disord 11: 314-321
22. Samuel W, Caligiuri M, Galasko D et al. (2000) Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 15: 794-802
23. Shea C, MacKnight C, Rockwood K (1998) Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 10: 229-238
24. Shiozaki K, Iseki E, Uchiyama H et al. (1999) Alterations ofmuscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: relation to Alzheimer's disease. J Neurol Neurosurg Psychiatry 67: 209-213
25. Shulman KI (2000) Clock-drawing: Is it the ideal cognitive screening test? Int J Geriatr Psychiatry 15:548-561
26. Simard M, Reekum R van (2004) The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci Fall 16: 409-425
27. Wesnes KA, McKeith IG, Ferrara R et al. (2002) Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord 13: 183-192
28. Zaccai J, McCracken C, Brayne C (2005) A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 34: 561-566